PHP
GOSS icon

Parkman Healthcare Partners’s Gossamer Bio GOSS Stock Holding History

Parkman Healthcare Partners’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200,185
Closed -$1.74M – 82
2022
Q1 		$1.74M Sell
200,185
-346,236
-63% -$3.34M 0.51% 50
2021
Q4 		$6.18M Sell
546,421
-240,449
-31% -$2.86M 1.36% 28
2021
Q3 		$9.89M Hold
786,870
– – 2.5% 12
2021
Q2 		$6.39M Buy
786,870
+203,980
+35% +$1.77M 1.4% 26
2021
Q1 		$5.39M Buy
582,890
+232,111
+66% +$2.34M 1.25% 27
2020
Q4 		$3.39M Buy
+350,779
New +$3.46M 0.87% 44

Other funds holding GOSS

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parkman Healthcare Partners's GOSS Position: Q2 2022 in Review

Parkman Healthcare Partners sold out of Gossamer Bio (GOSS) in Q2 2022, closing a stake of 200,185 shares — an estimated $1.74M sold.

Parkman Healthcare Partners first reported a position in GOSS in Q4 2020 and held it in 6 quarters. The position peaked at $9.89M in Q3 2021. 129 funds tracked by Wall St. Rank hold GOSS as of Q2 2022.

  • Parkman Healthcare Partners reported no remaining Gossamer Bio position as of Q2 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 200,185 Gossamer Bio shares in Q2 2022, an estimated $1.74M.
  • Parkman Healthcare Partners first reported a position in Gossamer Bio in Q4 2020 and held it in 6 quarters.
  • Parkman Healthcare Partners's Gossamer Bio position peaked at $9.89M in Q3 2021.
  • 129 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2022.

Based on Parkman Healthcare Partners's 13F filing for Q2 2022, filed 12 Aug 2022.